<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416116</url>
  </required_header>
  <id_info>
    <org_study_id>QTZ-EC-0002</org_study_id>
    <secondary_id>2010-023258-34</secondary_id>
    <nct_id>NCT01416116</nct_id>
  </id_info>
  <brief_title>Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch</brief_title>
  <acronym>LIFT</acronym>
  <official_title>Tolerability of QUTENZATM When Applied After Pre-treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A Randomized, Multi-center, Assessor-blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Summary of product characteristics (SmPC) for QUTENZA advises that topical anaesthetic is
      applied prior to the application of QUTENZA. This is a multi-center, randomized,
      assessor-blinded study which will investigate the use of an oral analgesic as an alternative
      form of pre-treatment for QUTENZA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be treated with QUTENZA for 60 minutes. Patients will be randomized to one
      of two arms- application of topical anaesthetic (lidocaine cream) or an oral analgesic
      (tramadol oral tables) prior to application of QUTENZA. Patients will be followed up for 7
      days to monitor pain scores and tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2011</start_date>
  <completion_date type="Actual">April 25, 2012</completion_date>
  <primary_completion_date type="Actual">April 25, 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects who tolerate QUTENZA treatment</measure>
    <time_frame>60 minute application period</time_frame>
    <description>A QUTENZA tolerant subject is defined as a subject receiving at least 90% of the intended patch duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of patch application</measure>
    <time_frame>60 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain scores from baseline to subsequent timepoints on the day of patch application</measure>
    <time_frame>5, 25, 55, 85, 115 minutes on day of application and once a day on days 1, 2, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects using pain medications and dose of pain medication(s) administered</measure>
    <time_frame>day 1-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject rated tolerability score</measure>
    <time_frame>Baseline to end of study visit, day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>or Peripheral Nerve Injury (PNI)</condition>
  <condition>Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)</condition>
  <arm_group>
    <arm_group_label>Tramadol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tramadol prior to QUTENZA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine prior to QUTENZA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QUTENZA</intervention_name>
    <description>topical</description>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_label>Tramadol</arm_group_label>
    <other_name>capsaicin 8% patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>topical</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>oral</description>
    <arm_group_label>Tramadol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of postherpetic neuralgia or neuropathic pain due to peripheral nerve injury

          -  Daily pain score ≥ 4 for average pain both at the Screening Visit and at the Treatment
             Visit

          -  Intact, non-irritated, dry skin over the painful area(s) to be treated

        Exclusion Criteria:

          -  Significant ongoing or recurrent pain other than due to PHN or peripheral nerve injury

          -  Past or current history of Type I or Type II diabetes mellitus

          -  Active malignancy or treatment for malignancy within a year prior to the Treatment
             Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Study Manager, Late Phase Clinical Development &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 202</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 203</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 201</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 302</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 301</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 402</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 403</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 404</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 401</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 502</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 501</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 603</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 602</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 702</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 701</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 704</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 703</name>
      <address>
        <city>Solihull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Ireland</country>
    <country>Norway</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=82</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2011</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tramadol</keyword>
  <keyword>QUTENZA</keyword>
  <keyword>Pre-treatment</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
    <mesh_term>Peripheral Nerve Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

